Thats the impression I'm getting. Ive had a look at a couple other forums and the focus seems to be mostly on Nuplaizaid and the forthcoming FDA decision. Indeed, some are treating trofinetide for Retts as a 'small market' with competition (which I won't name here). I think there is a small misinformed crowd in the US who are possibly overexcited retail investors baying for blood from the FDA, so trofinentide is getting lost in the cacophony there. They don't realise that the revenue potentially doubles for Acadia and will put them in the black.
Ann: Acadia submits Rett Syndrome New Drug Application to the FDA, page-53
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |